Skip to content
clinician talking with patient at desk

BioNova Announces First Patient Doses in a Phase 1/2 Study of BN301 for the Treatment of Hematologic Malignancies in China

BioNova Pharmaceuticals Limited (BioNova), a company dedicated to the discovery, development and commercialization of innovative medicines for the treatment of diseases with unmet medical needs, today announced that the first patient has been dosed in the phase 1 clinical study of BN301 (STRO-001) for the treatment of advanced B-cell Non-Hodgkin’s Lymphoma (NHL).

Back To Top